• 1
    Webb MS,Saltman DL,Connors JM,Goldie JH. A literature review of single agent treatment of multiply relapsed aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2002; 43: 975-982.
  • 2
    Gidding CE,Kellie SJ,Kamps WA,de Graaf SS. Vincristine revisited. Crit Rev Oncol Hematol. 1999; 29: 267-287.
  • 3
    Wood KW,Cornwell WD,Jackson JR. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol. 2001; 1: 370-377.
  • 4
    Kellie SJ,Koopmans P,Earl J, et al. Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer. 2004; 100: 2637-2643.
  • 5
    Webb MS,Harasym TO,Masin D,Bally MB,Mayer LD. Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br J Cancer. 1995; 72: 896-904.
  • 6
    Webb MS,Logan P,Kanter PM, et al. Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother Pharmacol. 1998; 42: 461-470.
  • 7
    Krishna R,Webb MS,St Onge G,Mayer LD. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J Pharmacol Exp Ther. 2001; 298: 1206-1212.
  • 8
    Harris NL,Jaffe ES,Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361.
  • 9
    Cheson BD,Horning SJ,Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17: 1244.
  • 10
    Rowinsky EK,Tolcher AW. Antimicrotubule agents. In: DeVitaJrVT, HellmanS, RosenbergSA, eds. Cancer: Principles & Practice of Oncology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2001: 431-452.
  • 11
    Rodriguez MA,Sarris A,East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for the elderly patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL) [abstract]. Proc Am Soc Clin Oncol. 2002; 21: 284a. Abstract 1132.
  • 12
    Rodriguez MA,Sarris A,East K, et al. A phase II study of liposomal vincristine in CHOP with rituximab for patients with untreated aggressive B-cell non-Hodgkin's lymphoma (NHL): a safe and effective combination [abstract]. Blood. 2002; 100: 92a. Abstract 338.
  • 13
    Rodriguez MA,Dang NH,Fayad L, et al. Sphingosomal vincristine in CHOP is a promising new treatment for elderly, as well as poor prognosis patients with aggressive non-Hodgkin's lymphoma (NHL): follow-up results of a phase II study [abstract]. Presented at 2004 ASCO Annual Meeting; June 5, 2004; New Orleans, LA. Abstract 8080.